内容紹介
Safety and Efficacy of Pegylated Liposomal Doxorubicin and Carboplatin on Platinum-Sensitive Recurrent Epithelial Ovarian Cancer
Summary
Objective: We evaluated the safety and efficacy of pegylated liposomal doxorubicin(PLD)and carboplatin(CBDCA)(CD)for platinum-sensitive recurrent epithelial ovarian cancer. Methods: From December 2010 to June 2011, 9 eligible patients with histologically confirmed, recurrent epithelial ovarian cancer, which was deemed platinum-sensitive, were enrolled onto the study. PLD(30 mg/m2)and CBDCA(area under the curve[AUC]5)were administered intravenously on day 1 of the cycle. The chemotherapy regimen was repeated every 4 weeks, until disease progression or completion of 6 cycles. Results: A total of 49 treatment cycles of CD were administered to 9 patients. The median platinum-free interval was 18.3 months. Patients with Grade 3/4 hematological toxicities were observed to have leucopenia(11.1%), neutropenia(44.4%), anemia(22.2%), and thrombocytopenia(22.2%). No Grade 3/4 non-hematological toxicities were observed, and no treatment-related death occurred. Seven patients(77.7%)responded to CD(4 complete responses and 3 partial responses). The median progression-free survival and overall survival times were 15.1 and 23.7 months. Conclusion: CD treatment seems to be a safe and effective chemotherapy regimen for platinum-sensitive recurrent epithelial ovarian cancer.
要旨
目的: プラチナ製剤感受性再発卵巣がんに対するリポソーマル化ドキソルビシン(PLD)+カルボプラチン(CBDCA)(CD)療法の安全性・有効性について検討した。方法: プラチナ製剤感受性再発卵巣がんで,適格基準を満たした症例にPLD 30 mg/m2とCBDCA AUC5をそれぞれday 1に投与し,28日ごとに病状の進行や重篤な有害事象がみられない限り6サイクルを目標に施行した。結果: 2010年12月～2011年6月まで9例に49サイクルを施行した。Grade 3以上の有害事象として白血球減少1例,好中球減少4例,貧血2例,血小板減少2例を認めたが,非血液毒性はみられなかった。治療効果は奏効率77.7%,無増悪生存期間中央値15.1か月,全生存期間中央値23.7か月であった。結論: プラチナ製剤感受性再発卵巣がんに対するCD療法は安全でかつ有効である可能性が示唆された。
目次
Summary
Objective: We evaluated the safety and efficacy of pegylated liposomal doxorubicin(PLD)and carboplatin(CBDCA)(CD)for platinum-sensitive recurrent epithelial ovarian cancer. Methods: From December 2010 to June 2011, 9 eligible patients with histologically confirmed, recurrent epithelial ovarian cancer, which was deemed platinum-sensitive, were enrolled onto the study. PLD(30 mg/m2)and CBDCA(area under the curve[AUC]5)were administered intravenously on day 1 of the cycle. The chemotherapy regimen was repeated every 4 weeks, until disease progression or completion of 6 cycles. Results: A total of 49 treatment cycles of CD were administered to 9 patients. The median platinum-free interval was 18.3 months. Patients with Grade 3/4 hematological toxicities were observed to have leucopenia(11.1%), neutropenia(44.4%), anemia(22.2%), and thrombocytopenia(22.2%). No Grade 3/4 non-hematological toxicities were observed, and no treatment-related death occurred. Seven patients(77.7%)responded to CD(4 complete responses and 3 partial responses). The median progression-free survival and overall survival times were 15.1 and 23.7 months. Conclusion: CD treatment seems to be a safe and effective chemotherapy regimen for platinum-sensitive recurrent epithelial ovarian cancer.
要旨
目的: プラチナ製剤感受性再発卵巣がんに対するリポソーマル化ドキソルビシン(PLD)+カルボプラチン(CBDCA)(CD)療法の安全性・有効性について検討した。方法: プラチナ製剤感受性再発卵巣がんで,適格基準を満たした症例にPLD 30 mg/m2とCBDCA AUC5をそれぞれday 1に投与し,28日ごとに病状の進行や重篤な有害事象がみられない限り6サイクルを目標に施行した。結果: 2010年12月～2011年6月まで9例に49サイクルを施行した。Grade 3以上の有害事象として白血球減少1例,好中球減少4例,貧血2例,血小板減少2例を認めたが,非血液毒性はみられなかった。治療効果は奏効率77.7%,無増悪生存期間中央値15.1か月,全生存期間中央値23.7か月であった。結論: プラチナ製剤感受性再発卵巣がんに対するCD療法は安全でかつ有効である可能性が示唆された。